Valeurs | |||||
Le rangement donne un aperçu de toutes les valeurs mobilières classées de manière alphabétique ou selon les indices. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Nom | Code | Analysis date | Cours de clôture | +/- % |
180 Life Sciences | ATNF | 13. jan 2025 | 1.49 | -1.32 |
22nd Century Group | XXII | 13. jan 2025 | 6.00 | +22.70 |
23andMe | ME | 13. jan 2025 | 3.64 | -5.21 |
2seventy bio | TSVT | 13. jan 2025 | 2.48 | -0.40 |
4D Molecular Therapeutics | FDMT | 13. jan 2025 | 4.76 | -13.77 |
60 Degrees Pharmaceuticals | SXTP | 13. jan 2025 | 0.92 | -12.36 |
AbbVie | ABBV | 13. jan 2025 | 176.74 | +0.90 |
AbCellera Biologics | ABCL | 13. jan 2025 | 3.00 | +2.74 |
Abeona Therapeutics | ABEO | 13. jan 2025 | 5.61 | +1.08 |
Abivax SA - American Depositary Shares | ABVX | 13. jan 2025 | 6.50 | +1.88 |
Absci | ABSI | 13. jan 2025 | 2.85 | -0.18 |
ABVC Biopharma | ABVC | 13. jan 2025 | 0.53 | -4.33 |
Ac Immune SA | ACIU | 13. jan 2025 | 2.61 | -4.04 |
Acadia Pharmaceuticals | ACAD | 13. jan 2025 | 17.90 | +3.71 |
Accel Entertainment | ACEL | 13. jan 2025 | 10.36 | +0.97 |
Accelerate Diagnostics | AXDX | 13. jan 2025 | 1.13 | -5.83 |
Acelyrin | SLRN | 13. jan 2025 | 2.15 | +4.37 |
Achieve Life Sciences | ACHV | 13. jan 2025 | 3.32 | -1.78 |
Achilles Therapeutics ADR | ACHL | 13. jan 2025 | 1.16 | -2.11 |
Aclaris Therapeutics | ACRS | 13. jan 2025 | 2.48 | +0.40 |
Acrivon Therapeutics | ACRV | 13. jan 2025 | 5.51 | +0.73 |
Actinium Pharmaceuticals | ATNM | 13. jan 2025 | 1.26 | -1.56 |
Actuate Therapeutics | ACTU | 13. jan 2025 | 8.08 | -2.65 |
Acumen Pharmaceuticals | ABOS | 13. jan 2025 | 1.59 | -3.64 |
Acurx Pharmaceuticals | ACXP | 13. jan 2025 | 0.70 | -13.39 |
Adagene ADR | ADAG | 13. jan 2025 | 1.78 | -8.01 |
Adagio Medical | ADGM | 13. jan 2025 | 0.89 | -6.60 |
Adaptimmune Therapeutics ADR | ADAP | 13. jan 2025 | 0.60 | -3.98 |
Adaptive Biotechnologies | ADPT | 13. jan 2025 | 6.46 | -0.62 |
ADC Therapeutics SA | ADCT | 13. jan 2025 | 1.72 | -8.51 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.